The new capital has allowed us to expand our commercial activities and to respond more quickly to the major opportunities in the market.Matthieu De Beule, CEO and co-founder FEops
Virtual heart surgery
FEops, a spin-off from UGent, develops simulation technology that enables doctors and manufacturers of cardiovascular implants to predict how a patient will react to a particular implant.
FEops’ HEARTguide platform is a cloud environment where doctors can plan different types of procedures and where manufacturers can virtually test their new implant designs. This allows doctors to avoid complications and companies to bring new devices more quickly to the market.
Partners in ambition at FEops
Since the last financing round in 2017 with Valiance, Capricorn and PMV, FEops has expanded its product offering and received important regulatory approvals for the use of the platform in Europe, the UK, Canada, Australia and the US.
In addition, revenue increased significantly and the company may enter into a number of strategic commercial partnerships. In December 2019, FEops received a 3.2 million euro grant through the European Innovation Council’s (EIC) accelerator programme.
For further expansion of the product range, staff retention and additional recruitment, FEops is now counting on a new round of funding in 2022. PMV has confidence in the expertise and market potential of FEops and is therefore prepared to provide additional funding.